CardiacAssist Builds a Bridge to the Next Bridge
This article was originally published in Start Up
Executive Summary
CardiacAssist operates in the market for acute heart failure, with TandemHeart a pump designed to reverse multi-organ failure, to help the heart recover, or at the very least, keep patients alive so they can move on to the next therapeutic option. A lot has happened since Start-Up spoke with CardiacAssist back in 2002. The company's TandemHeart gained 510(k) clearance in 2003, and by January 2009, more than 1,500 TandemHeart procedures had been performed. The pace of adoption is accelerating. Now, with sales of $10 million, and a steady 40% growth rate, the company is no longer dependent upon venture capital.
You may also be interested in...
Where Are They Now? Start-Up Revisits Cardiac Assist Companies
The market for cardiac assist devices has, in the past, been focused on end-stage patients waiting for a heart transplant, a niche market. But now, growth is accelerating in all sectors, from acute cardiac support to the long-term support of end-stage heart failure patients. Start-Up revisits CardiacAssist, CircuLite, and MicroMed.
Cardiac Assist: Pumping up the Heart Failure Market
After struggling for years to gain momentum, the ventricular assist device market appears finally to be coming of age. Second-generation VAD designs are performing well and seem to have largely addressed the pump durability and safety issues of the past that stymied growth and prevented this market from reaching its full potential. In the process, these new pumps, and their third-generation counterparts now waiting in the wings, are revitalizing interest in VADs among both physicians and patients, and propelling this potential multibillion dollar market to the forefront once again.
Abiomed: Heart Recovery, Not Replacement
David Lederman started Abiomed 25 years ago to develop an artificial heart, the AbioCor. While the AbioCor development continues, a new management team has broadened the company's focus. Where Abiomed once pioneered heart replacement, they now are breaking new ground in heart recovery. The challenge is whether, armed with new products and clinical data, the company can change physicians' treatment patterns for acute heart failure patients.